Publication:
Signaling pathways in liver fibrosis

dc.contributor.authorBAHAR, ASLI NUR
dc.contributor.authorsBAHAR A. N., AKBULUT K. G.
dc.date.accessioned2023-01-30T07:17:08Z
dc.date.available2023-01-30T07:17:08Z
dc.date.issued2023-01-01
dc.description.abstractLiver fibrosis is a disease characterized by activation of hepatic stellate cells (HSCs) and excessive accumulation of extracellular matrix (ECM) components that destroy the physiological structure of the liver. Liver fibrosis contributes to the increasing prevalence and severity of chronic liver diseases. If liver fibrosis, which is of great clinical importance, is not treated, it ends with cirrhosis, which is characterized by fatal and intense complications. Cirrhosis can progress to hepatocellular carcinoma. Although fibrosis was previously thought to be an irreversible process, studies have shown that because of the liver\"s high regenerative ability, regression and return to normal architecture is higher than in other tissues, even in advanced disease.Targeting signaling pathways that cause fibrosis and anti-fibrotic therapies are needed to prevent the progression of liver disease and the development of hepatocellular carcinoma (HCC). Activation of HSCs and transforming growth factor beta (TGF-beta), Wnt/beta-catenin signaling pathways and interactions play an important role in the pathogenesis of the disease. Sirtuins (SIRT) belong to the sirtuin family of Nicotinamide Adenine Dinucleotide, (NAD+) dependent protein deacetylases and are involved in many important cellular biological processes, including the inflammatory response, oxidative stress, and fibrosis. Sirtuin family has been shown to be involved in the regulation of fibrosis signaling pathways and in the cellular and molecular mechanisms of liver fibrosis. In this review, we aimed to summarize current knowledge about the signaling pathways that trigger differentiation, profibrotic activation of myofibroblasts and cause liver fibrosis that can be modulated by sirtuins.
dc.identifier.citationBAHAR A. N., AKBULUT K. G., "Signaling Pathways in Liver Fibrosis", GAZI MEDICAL JOURNAL, cilt.34, sa.1, ss.115-120, 2023
dc.identifier.doi10.12996/gmj.2023.24
dc.identifier.endpage120
dc.identifier.issn2147-2092
dc.identifier.issue1
dc.identifier.startpage115
dc.identifier.urihttps://hdl.handle.net/11424/285951
dc.identifier.volume34
dc.language.isoeng
dc.relation.ispartofGAZI MEDICAL JOURNAL
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectTemel Tıp Bilimleri
dc.subjectMedicine
dc.subjectHealth Sciences
dc.subjectFundamental Medical Sciences
dc.subjectTIP, GENEL & DAHİLİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectMEDICINE, GENERAL & INTERNAL
dc.subjectCLINICAL MEDICINE
dc.subjectClinical Medicine (MED)
dc.subjectGenel Sağlık Meslekleri
dc.subjectPatofizyoloji
dc.subjectTemel Bilgi ve Beceriler
dc.subjectDeğerlendirme ve Teşhis
dc.subjectDahiliye
dc.subjectAile Sağlığı
dc.subjectTıp (çeşitli)
dc.subjectGenel Tıp
dc.subjectGeneral Health Professions
dc.subjectPathophysiology
dc.subjectFundamentals and Skills
dc.subjectAssessment and Diagnosis
dc.subjectInternal Medicine
dc.subjectFamily Practice
dc.subjectMedicine (miscellaneous)
dc.subjectGeneral Medicine
dc.subjectHepatic stellate cell
dc.subjectliver fibrosis
dc.subjectsirtuin
dc.subjectTGF-
dc.subjectWnt
dc.subject-catenin
dc.subjectBETA-CATENIN
dc.subjectFIBROBLAST ACTIVATION
dc.subjectSIRTUIN 1
dc.subjectINHIBITION
dc.subjectMECHANISMS
dc.subjectMELATONIN
dc.subjectTARGET
dc.subjectINJURY
dc.subjectROLES
dc.subjectMICE
dc.titleSignaling pathways in liver fibrosis
dc.typearticle
dspace.entity.typePublication
local.avesis.idfec60cfa-4ba5-4d48-992d-b0a2f7567dba
local.indexed.atWOS
relation.isAuthorOfPublication0e10596b-a6cc-4e95-ace5-5dc379bebf5b
relation.isAuthorOfPublication.latestForDiscovery0e10596b-a6cc-4e95-ace5-5dc379bebf5b

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
11.pdf
Size:
1.13 MB
Format:
Adobe Portable Document Format

Collections